Granules Life Sciences gets U.S. FDA’s inspection report

Generic drugmaker Granules India’s Hyderabad-based pharmaceutical formulation intermediates and finished dosages manufacturing subsidiary Granules Life Sciences (GLS) has received constitution inspection study from the U.S. Food and Drug Administration (FDA).

The improvement confirms the facility’s compliance with FDA prime standards and regulatory requirements, the genitor institution said connected Friday, announcing the EIR. The installation underwent its archetypal U.S. FDA inspection from July 28 to August 01 which concluded with 1 observation.